StockTipsArenaBeta

BUY Cohance Lifesciences Limited — Goldman Sachs

BUYCohance Lifesciences Limited
Cohance Lifesciences share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)9 Nov 2026via ET Now (Live)

Entry₹439.05Inferred
Target₹525
Total upside +19.58%
Stop lossNot given
CMP₹458.61d ago
Active+4.45%+14.48%upside left 12 mo left
Follow Goldman Sachs for new calls(100% target hit, 47 closed calls)Get alertsWatch COHANCE for new buy/sell callsGet alertsSee 3 other Long-term calls on COHANCESee 272 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:32 am IST
5 supporting3 neutral6 opposing
Supports the BUY call (5)

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·21 Oct · 3w ago

Neutral / worth noting (3)

Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·6 Nov · 1w ago

(opens in new tab)
Weighs against the BUY call (6)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·13 Nov · yesterday

Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why

NewsNdtv-Profit·9 Nov · 5d ago

(opens in new tab)

Cohance Lifesciences Q2 Results: Net profit plunges 80% on lower revenue, unfavourable product mix

NewsCnbc-Tv18·6 Nov · 1w ago

(opens in new tab)

Cohance Lifesciences reported Q2 FY27 revenue of 4,767 million, a 14.2% year-on-year decline, and H1 FY27 revenue of 8,989 million, down 18.6% year-on-year, citing an unfavourable business and product

NSE · Press Release·6 Nov · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·6 Aug · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cohance Lifesciences

All analyst calls on Cohance Lifesciences

More from Goldman Sachs

Every call and its outcome